Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

ANTISENSE THERAPEUTICS LIMITED

INVESTOR PRESENTATION - ANTISENSE THERAPEUTICS LIMITED

ASX:ANP

ANTISENSE THERAPEUTICS LIMITED

Health Care

Antisense Therapeutics Limited (ANP.ASX) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly.

Read more

Market Cap

62.10m

Price at Close

$0.127

4w avg. Volume

1.96m

4w avg. Turnover

$261.00k

Announcements
announcementt+2 movementdate
  • Trading Halt

    Stock Exchange Announcement · Market sensitive

  • -

    22 Oct 2020

-

22 Oct 2020
  • Pause in Trading

    Stock Exchange Announcement · Market sensitive

  • -

    22 Oct 2020

-

22 Oct 2020
  • Quarterly Update and Appendix 4C

    Commitments test entity quarterly reports · Market sensitive

  • -5.93%

    20 Oct 2020

-5.93%

20 Oct 2020
  • Ceasing to be a substantial holder from AEF

    Shareholder Details

  • -5.93%

    20 Oct 2020

-5.93%

20 Oct 2020
  • Change in Substantial Holding from AEF

    Shareholder Details

  • -8.70%

    02 Oct 2020

-8.70%

02 Oct 2020
  • ATL1102 shows significant improvement vs external control

    Progress Report · Market sensitive

  • -16.00%

    01 Oct 2020

-16.00%

01 Oct 2020
  • US FDA Grants RPDD to ATL1102 for the treatment of DMD

    Stock Exchange Announcement · Market sensitive

  • +8.70%

    29 Sep 2020

+8.70%

29 Sep 2020
  • Antisense to present new data at WMS Virtual Congress 2020

    Progress Report · Market sensitive

  • +8.70%

    29 Sep 2020

+8.70%

29 Sep 2020
  • Trading Halt

    Stock Exchange Announcement · Market sensitive

  • +26.09%

    27 Sep 2020

+26.09%

27 Sep 2020
  • Ceasing to be a substantial holder

    Shareholder Details

  • +5.00%

    22 Sep 2020

+5.00%

22 Sep 2020
Market Data

Current Price

$0.127

52WK HIGH

$0.16

52WK LOW

$0.029

1YR RETURN

+27.00%

1YR RETURN VS. SECTOR

+8.26%

90 DAY RETURN

+27.00%

ASX RANK

976

/2,010

SECTOR RANK

12

/31

SHARES OUTSTANDING

488.99m
ASX:ANP

ANTISENSE THERAPEUTICS LIMITED

Health Care

Antisense Therapeutics Limited (ANP.ASX) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly.

Read more

Market Cap

62.10m

Price at Close

$0.127

4w avg. Volume

1.96m

4w avg. Turnover

$261.00k

ASX:ANP is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.